---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-22-008884"
form_type: "8-K"
ticker: "VNRX"
cik: "0000093314"
company_name: "VOLITIONRX LTD"
filed_at: "2022-11-25T23:59:59+00:00"
generated_at: "2026-06-21T13:12:11.353748+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# VolitionRx Chief Medical Officer Dr. Jason Terrell resigns effective Nov 18, 2022

## Summary
- Dr. Jason Terrell resigned as Chief Medical Officer on November 22, 2022, effective retroactively to November 18, 2022.
- Company thanked Dr. Terrell for his contributions and wished him success.
- No replacement for the CMO position was announced.

## SEC filing metadata
- accession: 0001477932-22-008884
- form_type: 8-K
- ticker: VNRX
- cik: 0000093314
- company_name: VOLITIONRX LTD
- filed_at: 2022-11-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/93314/000147793222008884/0001477932-22-008884-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/93314/000147793222008884/vnrx_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-22-008884
- JSON: https://secwatch.observer/filing/0001477932-22-008884.json
- Plain text: https://secwatch.observer/filing/0001477932-22-008884.txt

## Key facts
- Executive change
  Dr. Jason Terrell resigned as Chief Medical Officer at VOLITIONRX LTD.
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On November 22, 2022, Dr. Jason Terrell tendered written notice to VolitionRx Limited (the “Company”) of his resignation as Chief Medical Officer of the Company, effective as of November 18, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/93314/000147793222008884/0001477932-22-008884-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.